RICHELDI, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.993
EU - Europa 7.040
AS - Asia 3.640
SA - Sud America 436
AF - Africa 68
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 16
Totale 27.213
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.906
GB - Regno Unito 2.689
IT - Italia 1.404
CN - Cina 1.080
SG - Singapore 959
HK - Hong Kong 865
SE - Svezia 784
DE - Germania 529
UA - Ucraina 477
BR - Brasile 373
RU - Federazione Russa 306
TR - Turchia 293
FI - Finlandia 285
FR - Francia 170
BG - Bulgaria 166
IN - India 85
ID - Indonesia 80
KR - Corea 78
CA - Canada 62
NL - Olanda 62
VN - Vietnam 45
ZA - Sudafrica 33
BE - Belgio 30
IR - Iran 22
PK - Pakistan 22
NG - Nigeria 20
PL - Polonia 19
AR - Argentina 18
IQ - Iraq 18
IE - Irlanda 17
MX - Messico 17
AT - Austria 15
AU - Australia 14
BD - Bangladesh 13
EC - Ecuador 13
EU - Europa 13
AL - Albania 12
MY - Malesia 11
CH - Svizzera 10
TW - Taiwan 10
CZ - Repubblica Ceca 9
ES - Italia 9
JP - Giappone 9
UZ - Uzbekistan 9
CL - Cile 8
LT - Lituania 8
PE - Perù 8
CO - Colombia 7
TH - Thailandia 7
AZ - Azerbaigian 5
LV - Lettonia 5
RO - Romania 5
VE - Venezuela 5
DK - Danimarca 4
GR - Grecia 4
HR - Croazia 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
AM - Armenia 3
BO - Bolivia 3
EE - Estonia 3
JO - Giordania 3
KE - Kenya 3
KG - Kirghizistan 3
MA - Marocco 3
OM - Oman 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
BZ - Belize 2
IL - Israele 2
JM - Giamaica 2
MG - Madagascar 2
PA - Panama 2
PG - Papua Nuova Guinea 2
SA - Arabia Saudita 2
AD - Andorra 1
BY - Bielorussia 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
HN - Honduras 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
PS - Palestinian Territory 1
PY - Paraguay 1
RS - Serbia 1
SM - San Marino 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
Totale 27.213
Salva come PNG Salva come JPEG
Città #
Fairfield 2.176
Southend 2.014
Santa Clara 1.585
Woodbridge 1.472
Houston 1.134
Ashburn 1.114
Jacksonville 956
Chandler 921
Hong Kong 856
Seattle 817
Dearborn 752
Wilmington 707
Ann Arbor 696
Cambridge 690
Singapore 523
Nyköping 452
London 395
Beijing 254
Hefei 212
San Diego 191
Modena 186
Princeton 172
Sofia 164
Eugene 158
Helsinki 127
Izmir 123
New York 114
Council Bluffs 92
Milan 84
Shanghai 83
Moscow 79
Jakarta 62
Rome 59
Des Moines 57
Seoul 56
The Dalles 56
Naples 54
Palermo 50
Redwood City 49
Bremen 46
Boardman 34
Brussels 30
Phoenix 30
Norwalk 28
Guangzhou 27
Los Angeles 27
Dong Ket 26
Florence 26
Frankfurt am Main 25
Bari 24
Turin 23
Kunming 22
Chicago 21
São Paulo 21
Falls Church 19
San Francisco 19
San Mateo 19
Leawood 17
Philadelphia 16
Chennai 15
Dublin 15
Nanjing 15
Warsaw 15
Jinan 14
Toronto 14
Bologna 13
Indiana 13
Kilburn 13
Mountain View 13
Reggio Emilia 13
Verona 13
Hounslow 12
Wuhan 12
Dallas 11
Mumbai 11
Belo Horizonte 10
Cape Town 10
Lagos 10
Lahore 10
Nanchang 10
Ottawa 10
Pescara 10
Rio de Janeiro 10
Tirana 10
Boston 9
Chiswick 9
Holly 9
Rimini 9
San Jose 9
Seongnam 9
Zhengzhou 9
Columbus 8
Lucca 8
Montreal 8
Tashkent 8
Falkenstein 7
Fuzhou 7
Genoa 7
Lanzhou 7
Munich 7
Totale 20.674
Salva come PNG Salva come JPEG
Nome #
Malattie infiltrative diffuse del polmone 976
Multidrug-resistant tuberculosis outbreak in an Italian prison: Tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays 709
Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis. 363
Non-steroid agents for idiopathic pulmonary fibrosis 344
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 298
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study 272
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 272
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 268
Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patient 263
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. 254
Atypical lipomatous tumour (lipoma-like well-differentiated liposarcoma) arising in a pulmonary hamartoma and clinically presenting with pneumothorax 251
Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts 244
A culture-proven case of community-acquired Legionella pneumonia apparently classified as nosocomial: diagnostic and public health implications 244
Aortic pulse wave velocity measurement in systemic sclerosis patients. 244
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients 244
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study 241
Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis 236
Rifabutin for treating pulmonary tuberculosis. 235
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report 227
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 227
T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure 224
A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) 223
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis 221
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 221
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. 220
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis 217
Novel drug targets for idiopathic pulmonary fibrosis 216
Amyotrophic lateral sclerosis and sarcoidosis: a difficult differential diagnosis. 215
Pulmonary fibrosis and the many faces of UIP 213
Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. 212
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 209
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? 208
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 207
Unexpected identification of bilateral masses in an asymptomatic heavy smoker. 204
Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections 204
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung 202
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay 201
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials 200
Smoking-related interstitial lung disease 200
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience 200
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial 200
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients 199
Management of Idiopathic Pulmonary Fibrosis 198
Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. 195
T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infection. 193
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis 192
Macrolides in the treatment of asthma and cystic fibrosis 191
Prevalence and prognosis of unclassifiable interstitial lung disease 191
Sarcoidosis: challenging diagnostic aspects of an old disease. 190
Management of idiopathic pulmonary fibrosis. 190
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. 189
Emerging drugs for idiopathic pulmonary fibrosis. 188
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 185
The big clinical trials in idiopathic pulmonary fibrosis. 183
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis 179
Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed? 179
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias 177
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 176
MOLECULAR DIAGNOSIS OF TUBERCULOSIS 175
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. 174
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience 174
Tubercolosi 173
Identification Of Potential Candidate Biomarkers In Lymphangioleiomyomatosis Using ITRAQ Proteomic Technology 173
Performance of commerical blood tests for the diagnosis of latent tuberculosis infection in children and adolescents 173
An update on the diagnosis of tuberculosis infection 171
Immunomodulatory agents for idiopathic pulmonary fibrosis. 171
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. 170
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. 168
Genetic testing in diffuse parenchymal lung disease 168
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good 166
Role of the quantiferon-TB test in ruling out pleural tuberculosis: a multi-centre study. 166
Treating idiopathic pulmonary fibrosis: current opportunities and future challenges. 165
Inappropriatezza prescrittiva dell'ossigenoterapia domiciliare a lungo termine 165
The role of biomarkers in low respiratory tract infections. 164
Idiopathic pulmonary fibrosis: current challenges and future perspectives 164
End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. 163
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis 163
Early diagnosis of subclinical multi drug-resistant tuberculosis 162
Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. 162
The complex interrelationships between chronic lung and liver disease: a review. 161
Challenges in idiopathic interstitial lung disease 161
Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. 159
Screening dell’infezione tubercolare latente in operatori sanitari con QuantiFERON-TB e test cutaneo tubercolinico [Screening of latent tuberculosis infection in health care workers by QuantiFERON-TB and tuberculin skin test] 157
To BAL or not to BAL: is this a problem in diagnosing IPF? 156
Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice 156
Il cloroformio nell'aria alveolare di frequentatori di piscine coperte. 156
HLA-DPB1 Glutamate 69: a genetic marker of beryllium disease 155
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 153
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. 153
Interferon gamma assays for tuberculosis 152
Immunogenetic basis of environmental lung disease: lessons from the berylliosis model 152
Interaction of genetic and exposure factors in the prevalence of berylliosis 152
Co-trimoxazole effect on human alveolar macrophages of AIDS patients 152
Churg-Strauss syndrome in a case of asthma 152
Macrolides for chronic asthma. 151
Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing. 151
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial 151
Blood tests for diagnosis of tuberculosis - Reply 150
ANTIBODY REPERTOIRE AGAINST THE A60 ANTIGEN COMPLEX DURING THE COURSE OF PULMONARY TUBERCULOSIS 150
Idiopathic pulmonary fibrosis: recent trials and current drug therapy 150
Totale 20.784
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.881
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.881
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020263 0 0 0 0 0 0 0 0 0 0 0 263
2020/20213.561 347 180 355 291 366 262 292 444 165 417 243 199
2021/20222.903 86 488 275 221 59 87 200 108 293 208 525 353
2022/20232.694 324 274 169 241 317 402 47 292 331 81 116 100
2023/20242.023 62 129 124 173 372 244 245 244 67 47 128 188
2024/20255.791 212 90 84 417 1.236 847 389 367 631 357 585 576
Totale 27.411